Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
4,967 total articles
Gevo, Inc. President and COO Christopher Michael Ryan sold 129,797 shares across two days under a previously established 10b5-1 plan, reducing but not materially changing his direct stake. The transactions coincided with the stock trading close to its 52-week high, amid a quarter that delivered sharply higher revenue yet continued operating losses.…
Paula Soteropoulos, a director at Dianthus Therapeutics, sold 599 shares on March 31, 2026, at $80.11 per share for $47,985 and concurrently exercised options to acquire 599 shares at $8.44 per share. The stock has since risen to $84.54 and trades close to an InvestingPro-tracked 52-week high of $88.49 after a 402% gain over the past year. The tran…
Ryan Savitz, EVP, CFO and CBO of Dianthus Therapeutics, sold $9.5 million of company stock on March 31, 2026, and exercised options to acquire additional shares the same day. The transactions occurred under a Rule 10b5-1 plan adopted in late December 2025. Separately, Dianthus completed a public offering that generated roughly $719 million in gross…
David Young, President of Research & Development at Processa Pharmaceuticals, purchased 1,810 shares of the company on March 31, 2026, for $2.535 per share, a $4,588 transaction. Following the purchase Young's direct holding rose to 10,562 shares, with additional indirect holdings across a trust, family entities, and an LLC. Processa, a small-cap b…
A Processa Pharmaceuticals director purchased 2,072 shares on March 31, 2026, for $2.535 each, adding $5,252 to her direct stake as the company progresses a Phase 2 study and shows mixed recent stock performance. The transaction was disclosed in a Form 4 filing and follows recent clinical enrollment milestones.
Processa Pharmaceuticals Chief Executive Officer George K Ng purchased 2,136 shares of the company on March 31, 2026, for a total of $5,414. The transaction increases his direct and indirect holdings. Separately, the company has completed enrollment and dosing of 20 patients for an interim analysis in its Phase 2 study of NGC-Cap in advanced or met…
Brent W. Clum, Co-CEO and CFO of TXO Partners, L.P. (NASDAQ: TXO), sold 27,234 common units on April 1, 2026, at $12.38 per unit, generating proceeds of $337,156. After the transaction he holds 800,340 common units. The partnership has seen a year-to-date stock gain of 20.76% and is flagged as undervalued by InvestingPro, offering a 9.54% dividend …
Processa Pharmaceuticals Chief Financial Officer Russell Skibsted purchased 2,324 shares of the company on March 31, 2026, spending $5,891 at $2.535 per share. The trade was reported on a Form 4 and leaves Skibsted with direct ownership of those shares. The stock is trading at $2.60 with analysts setting a price target of $25, per InvestingPro data…
Patrick Lin, Chief Business - Strategy Officer at Processa Pharmaceuticals, acquired 1,603 shares of common stock on March 31, 2026, a purchase valued at $4,063. The transaction leaves Lin with 3,356 shares directly and 1,740 shares indirectly via the Lin Family Trust Feb 4, 2024. Separately, Processa has finished enrollment and dosing for a planne…
Ugwumba Chidozie, a ten percent owner of Clene Inc. (NASDAQ: CLNN), sold 4,278 shares on April 1, 2026, raising $21,261. The transaction occurred amid recent share volatility. Separately, Clene announced a registered direct offering in excess of $28 million to support its ALS candidate CNM-Au8 and secured an in-person Type C meeting with the FDA fo…
GitLab Inc. CEO William Staples acquired a total of $128,342 of Class A shares on March 31, 2026, in two transactions carried out under a pre-arranged 10b5-1 trading plan. The purchases occurred as the stock trades close to its 52-week low, with analysts divided on the company’s near-term outlook despite improving cash and cash-flow metrics.
Dolphin Entertainment CEO William O’Dowd IV acquired 3,100 shares of the company’s common stock on March 30, 2026, spending $4,867. The transaction brings his direct holdings to 456,290 shares, with additional indirect holdings through two wholly owned entities. The stock trades near its 52-week high amid volatility, and the company recently report…
Director Baluch Khoso bought 2,269 shares of Processa Pharmaceuticals (NASDAQ: PCSA) on March 31, 2026, for $2.535 per share, a $5,751 transaction that brought his direct holding to 2,325 shares. The stock has gained 9.78% over the last week but remains down 75% over the past year. Processa, trading at $2.60 with a market cap of $6.97 million, has …
Control Empresarial de Capitales S.A. de C.V., a roughly 10% owner of PBF Energy Inc (NASDAQ: PBF), disposed of 285,000 Class A common shares across two transactions on March 30 and March 31, 2026, generating about $14.5 million in proceeds. The share sales occurred while PBF stock has risen sharply over the past year and after the company reported…
CoreCivic Chief Administrative Officer Cole G. Carter sold 12,500 shares on April 1, 2026, for $18.94 each, generating $236,750 in proceeds and leaving him with 240,883 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan. CoreCivic reported fourth-quarter 2025 adjusted EPS of $0.27 versus consensus $0.24, and revenue of $604…
Chevron Chief Legal Officer Pate R. Hewitt sold 40,200 shares on March 30, 2026, generating $8.57 million, and simultaneously exercised options to acquire 40,200 shares at $125.35 per share. The transactions occurred while Chevron shares traded near a 52-week high and followed completion of the acquisition of Hess Corporation and governance changes…
UWM Holdings insiders sold just over 2 million shares at roughly $7.1 million on March 31 and April 1, 2026, under a previously established 10b5-1 plan. The transactions coincided with the company’s stock trading near a 52-week low, a sizeable dividend yield, recent quarterly outperformance, and active acquisition-related developments involving Two…
Robyn Tannenbaum, President and Chief Investment Officer of Advanced Flower Capital Inc., acquired 7,000 shares of common stock on March 31, 2026, paying $2.80 per share for a total of $19,600, according to a Form 4 filing. The transaction leaves her with substantial direct and indirect holdings. The move comes after the company reported a quarterl…
Leonard M. Tannenbaum, a director and 10% owner of Advanced Flower Capital Inc. (NASDAQ:AFCG), purchased 29,040 shares on March 31, 2026, paying an average price of $2.76 for a total of $80,150. The buy occurred while the stock had delivered a 10% return over the previous week. Separately, Advanced Flower Capital reported weaker-than-expected fourt…
Cytokinetics President and CEO Robert I. Blum sold 7,500 shares on April 1, 2026, at $66.63 per share for a total of $499,724. The sale occurred as the stock traded close to its 52-week high following a 76% gain over the past year. Analysts have issued several recent updates and raised price targets tied to the prospects for Myqorzo (aficamten) and…
Anthony R. Horton, a director at Team Inc. (NYSE: TISI), disclosed two open-market purchases in a Form 4 filing: 10,000 shares at $14.44 on March 20, 2026, and 3,000 shares at $16.19 on March 30, 2026. The combined outlay of $192,970 increases his direct holdings to 22,082 shares. The filings arrive against a mixed backdrop of strong fourth-quarter…
NeuroOne Medical Technologies Business Development Director Mark Christianson sold 15,363 shares on March 30, 2026 and another 253 shares on March 31, 2026. The transactions, disclosed in a Form 4 filed April 1, 2026, followed the company’s Q1 Fiscal 2026 results and came as the stock traded around $0.80. Analysts maintain price targets from $1.50 …
Vitesse Energy director Dan O’Leary purchased 10,000 shares on March 31, 2026, at $18.56 per share, bringing his direct holdings to 33,789 shares. The transaction occurred as the stock traded near a 52-week low and the company reported a large EPS shortfall alongside a revenue beat, implemented commodity hedges covering much of 2026 production, and…
Atul Dandekar, Maze Therapeutics' Chief Strategy and Business Officer, sold 7,500 shares of the company on March 30, 2026, for $220,018 and exercised options to buy 7,500 shares at $10.42 the same day. The transactions leave him with 10,503 shares and were carried out under a Rule 10b5-1 plan established in September 2025. Maze recently disclosed P…
CoreWeave Chief Development Officer Brannin McBee executed roughly $9.9 million in sales of Class A Common Stock on March 30, 2026, across several blocks and at prices between $67.67 and $75.19 per share. The sales - made directly, via an irrevocable trust, and through shares held by a spouse - were conducted under a pre-arranged Rule 10b5-1 plan a…
